Conclusion
obesity, cardiometabolic complications
OBESITY
Collectively, the current study implied that supplementation of multistrain/multispecies synbiotic (250 mg/day) concomitant with L-carnitine (2 × 500 mg/day) for 8 weeks resulted in greater amendment in anthropometric and glycemic indices, and HDL-C in healthy female individuals with obesity without any severe side effects, indicating that L-carnitine + synbiotic co-supplementation seems to be more beneficial to ameliorate the mentioned parameters, compared with L-carnitine individual therapy.In conclusion, our findings suggest that co-administration of L-carnitine and synbiotic may be an encouraging therapeutic strategy for obesity and related cardiometabolic complications, possibly due to simultaneous targeting of multiple metabolic pathways, augmenting their bioavailability/function through potential complementary or synergistic mechanisms. Moreover, co-encapsulation of synbiotics and L-carnitine as a single microcapsule could be considered as a conceivable delivery system to enhance the stability and efficacy of synbiotics as well as to reduce the cost of the final product.Further mechanistic investigations are warranted to clarify the exact mechanisms mediating the synergistic effect of L-carnitine and synbiotic combined therapy on weight and metabolic parameters.